DermDocs: Recent Episodes
LivDerm
The management of hidradenitis suppurativa (HS) is evolving, but many patients still face significant hurdles in achieving optimal outcomes with current therapies. In this episode, "JAK Inhibition and the Future of HS Treatment," expert dermatologists, Hadar Lev-Tov, MD, and Jennifer L. Hsiao, MD discuss:
- Increasing Awareness: Debunking common myths and misconceptions about HS.
- Building Trust: Strategies for overcoming diagnostic delays and insufficient management.
- Comprehensive Care: Adopting a holistic approach, including addressing common comorbidities.
- The Road Ahead: Exploring the future of the HS treatment landscape, including JAK inhibition.
This is the final installment of our 4-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." In this episode, "Moving into the Non-Steroidal Topical Therapy Age," we dive into the current and emerging landscape of targeted topical therapies for AD patients. Our experts review the latest clinical data, discuss how they are practically integrating these agents into their practice, and analyze the resulting impact on patient outcomes and their overall approach to AD management. Listen in as board-certified dermatologists, Mona Shahriari, MD and G. Michael Lewitt, MD discuss:
- Overview of targeted topical therapies, including next generation topicals
- Efficacy of targeted topicals compared to topical steroids
- Safety, limitations, and compatibility with other therapies
- How to integrate targeted topicals into clinical practice
- Pearls for treating pediatric and adult patients across the indicated age range
This podcast is supported by an educational grant from Arcutis Biotherapeutics, Inc.
The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss:
- Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology
- Long-term safety of topical therapies for chronic AD
- Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial
- Shifting the paradigm of topical AD care across patient populations
This is the third part of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." This episode, "Addressing Patient Concerns Regarding Treatment of Dermatoses Using Steroids," focuses on the importance of patient education and shared decision-making.
In this episode, supported by an educational grant from Arcutis, expert dermatologists Mona Shahriari, MD and Alexandra Golant, MD discuss how to effectively inform and de-escalate concerns from patients and caregivers regarding steroid treatments for atopic dermatitis.
Join us as we explore:
- The risks and benefits of using topical steroids and non-steroidals.
- How to involve patients in their treatment decisions.
- Managing side effects from topical steroids, especially for patients with skin of color.
- Tips for helping patients with daily AD care.
- Pearls for patient education.
In the second installment of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD," we're tackling a topic that's often misunderstood and highly challenging: Topical Steroid Withdrawal (TSW). Supported by an educational grant from Arcutis, this episode, "Topical Steroid Withdrawal – Myths vs Science," features expert dermatologists Dr Mona Shahriari, MD, and Dr Peter Lio, MD.
Join us as we separate fact from fiction and dive deep into:
- The common pitfalls of overusing or misusing topical corticosteroids (TCS)
- How to recognize the telltale signs and symptoms of TSW
- Effective and compassionate strategies for managing TSW
- The key to using TCS responsibly
- Understanding when to pivot to targeted, non-steroidal treatments.
For those interested in the science behind TSW, we've included a link to a recent publication on the disease mechanism: Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD - PubMed
This is the first episode of a four-part series, “Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD,” supported by an educational grant from Arcutis. In this episode, “Steroidal vs Non-Steroidal Topicals – Case by Case Discussion,” expert dermatologists, Mona Shahriari, MD and James Song, MD, discuss: * Appropriate use of topical corticosteroids and targeted topicals for atopic dermatitis * Benefits of topical corticosteroids and remaining unmet needs * How new targeted topicals fit into the atopic dermatitis toolbox and improve adherence to therapy * Case-based discussion of targeted topicals for the treatment of AD.
In this episode, entitled “JAK Inhibition for Treatment of Vitiligo,” expert dermatologists, Dr Andrew Alexis, MD, MPH and Dr Erik Domingues, MD, FAAD, discuss the following topics: · Changing the culture of vitiligo care · Diagnosing vitiligo and associated comorbidities · Strategies for managing vitiligo and educating patients about treatment options · Setting patient expectations for the treatment process
This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics:
- Mechanism of action for IL-31 inhibitor nemolizumab
- Clinical safety and efficacy data for nemolizumab for treatment of PN
- Strategies for prescribing IL-31 inhibitors in clinical practice
- Pearls for patient selection and addressing treatment challenges
This is the second episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, is joined by Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, as they discuss the following topics:
- Setting the stage for treating a patient with EB
- Assessing EB severity and subtype to inform treatment
- Expert review of the current FDA-approved treatments and
- Strategies to close care gaps for EB patients
This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics:
- Challenges in achieving treatment targets in AD
- Therapeutic inertia and clinical implications of inadequate response
- Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD
- Transitioning to systemic therapies from topical agents, immunosuppressives, and biologic therapies
This is the first episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, is joined by Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, as they discuss the following topics:
- Epidemiology and prevalence of EB
- Burden of disease and impact on patients' quality of life
- Gaps and challenges for patients with EB
- Assessing the current knowledge of clinicians and gaps in care recommendations
This podcast episode, sponsored by Leo Pharma, features LiVDerm faculty and esteemed dermatologists Dr. Christopher Bunick, MD, PhD, and Dr. Jonathan Silverberg, MD, PhD, MPH. As experts in all things concerning eczema, our faculty discuss the differentiating features and disease burden in patients suffering from chronic hand eczema (CHE) and review the current guidance for treatment, including these specific topics:
- Differentiating CHE from atopic dermatitis of the hands, including triggers, pathophysiology, and clinical presentation
- Expert guidance for accurate diagnosis and work-up of CHE patients
- Challenges and limitations of current therapeutic offerings
- The potential of a topical novel pan-JAK inhibitor for targeted treatment of CHE
This is the first episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma and hosted by prurigo nodularis (PN) expert Dr. Shawn Kwatra, MD. This episode, "Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis", featuring expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, discusses the following topics:
- The lack of awareness and timely, correct diagnosis of PN patients
- Strategies for assessing patients with PN and alleviating disease symptoms and burden
- Examining the current expert guidance and available therapies for treating PN
- Looking to the future of PN diagnosis and targeted treatment
This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics:
- The pros and cons of steroid use in treating AD
- Targeted non-steroidal topical therapies approved by the FDA
- Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals
- Recommendations for long-term symptom control in AD patients
This is the fifth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?", featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics:
- Mechanistic differences between JAKi and biologics for treatment of AD
- Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics
- Pearls for prescribing JAKi to AD patients
- Strategies for choosing JAKi vs biologics based on safety and patient factors
This is the first episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Dangers and Side Effects of Steroid Exposure in Treatment of AD", featuring expert dermatologist Dr. Peter Lio, MD, discusses the following topics:
- Side effects of topical and oral corticosteroid exposure
- Pearls and gaps in current guidelines for treatment of AD
- Identifying topical steroid withdrawal symptoms
- Safety and stewardship strategies for topical steroids
- Future of non-steroidal advanced topical therapies for AD
Record Date: 8/6/2024
This is the fourth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy", featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics:
- Identifying ideal candidates for oral JAK inhibitor therapy
- Steps to initiate therapy and onboard new patients
- How to manage side effects and maintain adherence to treatment
- Case examples and real-world data
This is the third episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics:
- Overall impact of atopic dermatitis on patients' quality of life
- Overview of the role of various existing treatments for AD and expert guidelines
- Discussion of LEVEL UP clinical trial data comparing upadacitinib and dupilumab
- Defining treatment success and best practices for treatment selection
www.livderm.org
This special podcast episode, developed in collaboration with UCB, features LiVDerm faculty and esteemed dermatologists Dr. Jennifer Hsiao, MD, and Dr. Hadar Lev-Tov, MD. As experts in all things hidradenitis suppurativa (HS), our faculty discuss the need for early and accurate diagnosis and assessment of patients with HS in order to prescribe treatment at the best time to achieve disease control, including the following topics:
- Key challenges in treating patients with moderate-to-severe HS
- The role of targeted, systemic therapies in HS management
- Defining "moderate" disease and strategies for severity assessment
- Defining window of opportunity and strategies for advanced treatment of HS
- Defining and assessing treatment response and success with targeted therapies
This is the second episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis", featuring expert dermatologist Dr. James Song, MD, discusses the following topics:
- Short- and long-term efficacy and safety data for JAK inhibitor therapies
- New topline data from the LEVEL UP trial studying upadacitinib in comparison to dupilumab for the treatment of patients aged 12 years and older with moderate-to-severe AD
- Head-to-head studies and real-world evidence evaluating JAK inhibitor therapies
- Emerging clinical developments and what's coming next in JAK inhibitor research
This is the fourth and final episode of the, "Psoriasis in Skin of Color Unplugged" series, hosted by expert dermatologist Dr. Mona Shahriari who will be discussing the gaps in care for psoriasis patients with skin of color. This episode, “Patient and Disease Advocacy”, featuring Jason Harris, the VP of Government Relations and Advocacy at the National Psoriasis Foundation (NPF), discusses the following topics:
- Patient perspective on challenges to receiving treatment for their psoriasis
- NPF efforts to address patient challenges and access to care issues
- Relevant survey and research data on disparities specific to SoC and socioeconomic status
- Consideration of impact on quality of life in determining access to systemic treatments
If you have any questions about NPF efforts to advocate for patients with psoriasis, please reach out to Jason Harris via email at jharris@psoriasis.org or visit the NPF website.
This is the third episode of the, "Psoriasis in Skin of Color Unplugged" series, hosted by expert dermatologist Dr. Mona Shahriari who will be discussing the gaps in care for psoriasis patients with skin of color. This episode, “Advancing Diversity and Inclusion in Clinical Trials”, featuring expert dermatologists Dr. Andrew Alexis and Dr. Jennifer Soung, discusses the following topics:
- Underrepresentation of diverse patients, investigators, and trial sites in clinical studies
- FDA efforts to improve clinical trial diversity and education
- The impact that current clinical trials focusing on SOC are having on patient care
- High-level findings from the VISIBLE trial studying psoriasis patients of color
www.LiVDerm.org
This is the second episode of the, "Psoriasis in Skin of Color Unplugged" series, hosted by expert dermatologist Dr. Mona Shahriari who will be discussing the gaps in care for psoriasis patients with skin of color. This episode, “Gaps in Diagnosis and Dermatologist Training”, featuring expert dermatologist Dr. George Han, discusses the following topics:
- Difference in clinical presentation of psoriasis in SoC
- Barriers to early and accurate diagnosis and dangers of delayed diagnosis
- Gaps in medical student and residency education
- Lack of SoC images in medical textbooks, public images, and advertising
Launch date is May 7
This is the first episodes of a new series, "Psoriasis in Skin of Color Unplugged", hosted by expert dermatologist Dr. Mona Shahriari who will be discussing the gaps in care for psoriasis patients with skin of color. This episode, “Disparities and Access to Care”, featuring expert dermatologist Dr. Candrice Heath, discusses the following topics:
- Increased severity of psoriatic disease in patients of color
- Challenges associated with access to specialist care
- Stigma surrounding psoriasis in patients of color
- Gaps in culturally competent care
www.LiVDerm.org
This is the first episodes of a new series hosted by expert dermatologist Dr. Christopher Bunick who will be discussing the evolving role of JAK inhibitor therapies in the management of atopic dermatitis (AD). This episode, "The Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors", featuring expert dermatologist Dr. John Koo, discusses the following topics: * Understanding atopic dermatitis as a spectrum disorder, phenotypes and endotypes, and heterogeneity of atopic disease * Summarizing JAK inhibitor therapies, including clinical safety and efficacy and mechanism of action * Comparison of JAKi to biologics and traditional systemic agents, and the evolving role of JAKi in treatment of AD
LiVDerm.org
n support of Eczema Awareness Month, LiVDerm sat down with one of the nation’s top experts on atopic dermatitis, Christopher G. Bunick, MD, PhD, to discuss this widespread skin condition that affects millions worldwide.
Associate professor of dermatology at Yale University School of Medicine, Dr. Bunick covers emerging targeted therapies and also looks at the concerns over their safety and efficacy. He also addresses some of the gaps that persist in treatment despite these new therapies.
In support of Eczema Awareness Month, LiVDerm sat down with one of the nation’s top experts on atopic dermatitis, Peter A. Lio, MD, to discuss this widespread skin condition that affects millions worldwide.
Dr. Lio, a clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, focuses on caring for pediatric patients with eczema in his interview. He provides unique insight into how best to combine integrative and pharmacologic treatments.
Natasha A. Mesinkovska, MD, PhD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, speaks out about comorbid conditions often seen in alopecia areata patients, as well as her personal approach to treatment.
Questions:
- We’ve heard a lot about comorbid conditions often seen in patients with alopecia areata. Do you have any pearls you’d like to share regarding screening or multidisciplinary care for patients with comorbidities?
- What is your personal approach to developing a treatment plan for your patients with alopecia areata?
- Thank you for your time today, Dr Mesinkovska. This was very informative. Is there anything else you’d like to add?
Date: February 10, 2023
Brett King, MD, PhD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, speaks out about the rising use of JAK inhibitors to treat patients with alopecia areata.
Questions:
- JAK inhibitors are taking the dermatology field by storm, with several approvals for multiple dermatologic conditions over the past couple of years. What is it that makes JAK inhibitors a gamechanger for treatment of alopecia areata?
- In 2022, the first ever targeted treatment for alopecia areata, baricitinib, was approved by the FDA for adult patients. What additional treatments or FDA approvals can we expect to see in 2023?
- Thank you for your time today, Dr King. This was fantastic. Is there anything else you’d like to add?
Date: February 10, 2023
Brittany Craiglow, MD, who spoke on the live satellite symposium "Gamechangers in Alopecia Areata" at the SBS 2023 meeting, shares her personal approach to treating pediatric patients with alopecia areata.
Questions:
- What is your personal approach to developing a treatment plan with your patients and/or their caregivers? Do find yourself utilizing shared decision-making or other nuances to communicating with patients and caregivers?
- You mainly treat pediatric and adolescent patients for hair loss in your clinical practice. Are there any specific nuances you’d like to share in regard to treating pediatric versus adult patients suffering from hair loss?
- Thank you for your time today, Dr Craiglow. This was wonderful. Is there anything else you’d like to add?
Recorded Date: February 10, 2023
Elaine Siegfried, MD, who spoke on the live satellite symposium "Infants and Atopic Dermatitis" at the MOPD 2023 meeting, shares her expert advice for formulating a treatment plan and incorporating newer treatment options when managing pediatric patients with atopic dermatitis.
Questions:
- With recently expanded age indications for therapeutic agents to treat pediatric AD, what steps should clinicians consider when formulating a treatment plan for their younger patients?
- The treatment landscape for atopic dermatitis in pediatric patients has shown much growth over the past couple of years. How do you foresee the treatment landscape continuing to change in 2023?
- This was excellent, Dr Siegfried, thank you for your time. Is there anything else you’d like to add?
Date: February 10, 2023
Lawrence Schachner, MD, chair of the MOPD meeting and expert faculty who spoke on the live satellite symposium "Infants and Atopic Dermatitis", shares clinical pearls for early and accurate diagnosis of atopic dermatitis in younger pediatric patients, as well as challenges often faced when assessing pediatric patients with skin of color.
Questions:
- Can you share your top pearls for early and accurate recognition of atopic dermatitis in infants?
- What gaps do you feel persist in the diagnosis and assessment of atopic dermatitis in infants, particularly those with skin of color?
- Thank you for your time today, Dr Schachner. This was fantastic. Is there anything else you’d like to add?
Date: February 10, 2023
Mercedes Gonzalez, MD, who spoke on the live satellite symposium "Infants and Atopic Dermatitis" at the MOPD 2023 meeting, shares clinical pearls for improving communication with patients and caregivers of patients with atopic dermatitis.
Questions:
- Caregivers often voice concerns regarding safety and side effects of newer systemic treatments for atopic dermatitis. What can clinicians do to better educate and reassure their patients and caregivers? How does shared decision-making factor into this?
- What gaps do you feel persist regarding the communication between clinicians and their patients/caregivers? What can clinicians do to address these gaps?
- Thank you for your time today, Dr Gonzalez. This was very informative. Is there anything else you’d like to add?
February 10, 2023
Peter Lio, MD, LiVDerm faculty and atopic dermatitis expert, shares pearls from his session at the SBS 2022 event regarding the efficacy and safety of IL-13 inhibitors for treatment of AD.
- What factors should clinicians consider when selecting a biologic or systemic therapy to manage atopic dermatitis?
- Effectively and promptly diagnosing atopic dermatitis can be a bit tricky at times. What is your personal approach for effective diagnosis?
- Which patients would benefit most from an integrative approach to managing atopic dermatitis?
- How can clinicians execute effective shared decision-making strategies in the management of chronic skin conditions?
Peter Lio, MD, LiVDerm faculty and atopic dermatitis expert, shares pearls from his session at the SBS 2022 event regarding the efficacy and safety of IL-13 inhibitors for treatment of AD.
- What factors should clinicians consider when selecting a biologic or systemic therapy to manage atopic dermatitis?
- Effectively and promptly diagnosing atopic dermatitis can be a bit tricky at times. What is your personal approach for effective diagnosis?
- Which patients would benefit most from an integrative approach to managing atopic dermatitis?
- How can clinicians execute effective shared decision-making strategies in the management of chronic skin conditions?
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
- With the several ongoing advances in the availability of more treatment options for managing atopic dermatitis, how can the practicing clinician best select the most appropriate treatment option that will address the underlying causes of disease progression?
- As with most treatment options for chronic conditions, side effects often occur. What considerations should clinicians remember when discussing treatment-related adverse events with their patients?
- Atopic dermatitis is stated to impact several areas of a patient’s life, including the quality. How can clinicians best address this issue from a patient-centered perspective?
- What key takeaways should clinicians consider when constructing a management plan for chronic illnesses such as moderate to severe atopic dermatitis?
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
- With the several ongoing advances in the availability of more treatment options for managing atopic dermatitis, how can the practicing clinician best select the most appropriate treatment option that will address the underlying causes of disease progression?
- As with most treatment options for chronic conditions, side effects often occur. What considerations should clinicians remember when discussing treatment-related adverse events with their patients?
- Atopic dermatitis is stated to impact several areas of a patient’s life, including the quality. How can clinicians best address this issue from a patient-centered perspective?
- What key takeaways should clinicians consider when constructing a management plan for chronic illnesses such as moderate to severe atopic dermatitis?
We are honored to speak to Klint Peebles, MD, the chair of LiVDerm's Sexual and Gender Diverse Dermatology Summit: Fundamentals and Practical Pearls and past chair of the American Academy of Dermatology’s Expert Resource Group on Sexual and Gender Diverse Health. Dr. Peebles, a board-certified dermatologist with Kaiser Permanente, Mid-Atlantic Permanente Medical Group, has extensive clinical, leadership, and research expertise in sexual and gender diverse health and gender-affirming dermatology. Dr. Peebles currently serves on the LGBTQ Health Specialty Section Council of the American Medical Association. Dr. Peebles mentions some of the key reasons why you don't want to miss the Sexual and Gender Diverse Dermatology Summit: Fundamentals and Practical Pearls in California October 15-16, 2022! - Register here: www.livderm.org/live-events/sexual-and-gender-minority/
Topics Dr. Peebles covers include:
- We are so excited to welcome you as the conference chair of our upcoming Sexual and Gender Diverse Dermatology Summit in Southern California this October 15-16. What unique experiences do you bring to this conference and why is this patient population so important in the dermatologic field?
- Although there are certain aspects of aesthetic medicine in caring for sexual and gender diverse patients, would you consider this area of the discipline falling under the category of medical dermatology, or is it not necessary to differentiate? Do you expect practitioners of both cosmetic and general dermatology to benefit from the Summit?
- Your wealth of experience, leadership, and advocacy in the field of better medical care for the sexual and gender diverse patient population has no doubt improved outcomes and quality of life. Can you tell us about some of your career highlights and moments when you could see actionable change as a result of your efforts?
- The Sexual and Gender Diverse Summit, taking place within SBS: West Coast Derm this October 2022 at the Terranea Resort is a milestone event for LiVDerm. Do you think the location of the event just outside of Los Angeles, California, is indicative of the sexual and gender diverse population and the providers who see them? Do you see events like this someday soon being held in smaller, more rural regions of the U.S. where fewer resources or social determinants may mean that sexual and gender diverse patients face even larger roadblocks to care?
- Is the field of dermatology seeing improvements in nondiscrimination, acceptance, welcoming environments, affirming language, and dedicated initiatives to improve safety, and can you explain some of those efforts within the context of guidelines or policy?
www.livderm.org
Internationally renowned dermatologist, Doris Day, MD, who recently was named one of the top 5 dermatologists in America for 2022, gives us the latest updates in aesthetic and medical dermatology. She also mentions some of the key reasons why you don't want to miss the upcoming South Beach Symposium in Miami, FL - and SBS West in California!
Dr. Day specializes in laser, cosmetic and surgical dermatology. She lectures nationally and internationally on the latest aesthetic techniques to both her peers and to the public. As a highly respected and sought-after personality in the area of cosmetic dermatology, Dr. Day has been featured in the media, and serves on medical advisory boards and training panels where she teaches other physicians the art of soft tissue fillers, laser treatments and facial rejuvenation techniques.
Don't forget to rate, subscribe or follow DermDocs, and leave us a five star review!
Topics she covers include:
- You are sought after not only by patients for your clinical expertise, but also by the media to weigh in on trending topics in cosmetic dermatology. How did you cultivate such a respected position in this industry, and what responsibilities come with having such a wide reach?
- You're also an author. Did you enjoy the writing process, and do you think you'll publish more books in the future?
- This August, LiVDerm is honored to welcome you back to Miami Beach for the 20th Anniversary of South Beach Symposium. Tell us a bit about the history of the event and what aspects you look forward to each year.
- You'll deliver sessions at this year's South Beach Symposium addressing important topics in both aesthetic and medical dermatology. Do some topics, such as female sexual rejuvenation, actually encompass both disciplines?
- South Beach Symposium is extending our reach this October by hosting a conference in California. As an East Coaster, what differences do you think attendees at SBS: West Coast Derm can expect from education focused on the aesthetic needs of West Coast clientele?
Please listen as nationally-renowned innovator, artist, and scientist, Jason J. Emer, MD, shares the secrets to redefining perfection.
Dr. Emer is well-known throughout the nation as the master of his field. He is redefining the world of liposuction and body shaping, one impeccably-sculpted client at a time. Dr. Emer pushes the boundaries of what’s possible – earning him a well-deserved reputation as the man behind some of Beverly Hills’ most notorious bodies. This is a must-listen episode!
Don't forget to rate, subscribe or follow DermDocs, and leave us a five star review!
Topics he covers include:
- Because June is Men's Health Month, LiVDerm is featuring some topics that pertain specifically to men. You specialize in both surgical and nonsurgical methods to reshape the nose. How do these services relate specifically to your male patients - and have you seen an increase in demand from male patients in recent years?
- South Beach Symposium is expanding our reach to the West Coast for a first-ever conference this October 14-16. As one of the most prominent dermatologists in California, what can the audience expect from SBS: WEST COAST DERM, a meeting geared towards the needs of a West Coast clientele?
- Can you give our listeners a glimpse into plasma pen treatments for nonsurgical skin rejuvenation and explain why patients have been so enthusiastic about these treatments and the results?
- How can chemical peel treatments enhance the results of injectables like fillers and botox?
- Why is the heart-shaped face such a visually appealing aesthetic, and what injection techniques can providers use to achieve it?
- And finally, we are so excited to welcome you to Miami Beach this August for your much-anticipated sessions at South Beach Symposium! Among all the topics you'll be covering, you'll also take part in the Star Panel: Expert-Led Discussion of Practice Management for Cosmetic Dermatologists. Why is it so important for dermatologists to come together in forums like this, and what can attendees learn from these interactions between the experts beyond just a traditional lecture?
www.livderm.org
Listen as world-renowned dermatologist, Michael H. Gold, MD, FAAD, gives us great insight on energy-based devices, and how they treat a myriad of skin conditions. He also uncovers the latest advances in scar treatment. It's an episode you won't want to miss!
Dr. Gold is a board-certified dermatologist and dermatologic surgeon. He is world-renowned for providing patients with leading-edge technological advances in dermatology. He was also recently named one of the top three dermatologists in Nashville.
Don't forget to rate, subscribe or follow DermDocs, and leave us a five star review!
Topics he covers include:
1 . You are regularly named to top doctors lists, and were recently named one of the three best dermatologists in Nashville. What's your philosophy for maintaining a robust clientele and high patient satisfaction? Can attendees at South Beach Symposium expect to learn ways to improve their business practices, in addition to cutting-edge clinical techniques?
-
You are world-renowned for your expertise in energy-based devices to treat a myriad of skin conditions. Tell us about the success you've seen specifically using EBDs in patients with skin of color.
-
Tell us a little about the sessions you'll be presenting at this year's South Beach Symposium. Are there similarities in treating both acne and rosacea with energy-based devices? And what will attendees learn in your session on microneedling?
-
Are lasers for hair loss the future of alopecia treatment? Briefly, how do they work, what is the course of treatment, and how can providers predict or determine which patients will see improvements? Is this treatment specifically for alopecia-related hair loss, or does it translate to male-pattern and age-related hair loss and thinning, as well?
-
You are on the cutting-edge of new approaches in scar treatment. Is this an area where medical and cosmetic dermatology collide? What is the latest technology in this area? Are there challenges to achieving optimal results that providers should be aware of?
Dr. Z. Paul Lorenc, M.D., shares insights about cellulite protocols, facial structure techniques, and important information about why you should attend his live cadaver workshop this fall. Other topics he covers in this part 2 special include: When deciding how to manage cellulite, which patient characteristics do you consider most strongly when selecting a course of treatment? Why is an understanding of facial anatomy so important, particularly in the lower face and jaw, for providers when selecting injection patterns?
You may know that South Beach Symposium is expanding to the West Coast this Fall. Because you practice in New York but teach and lecture nationwide, do you notice different aesthetics on the East vs. West Coasts?
What might a West Coast provider audience be more interested in learning based on their patients’ needs?
LiVDerm education isn’t just for dermatologists. How would you say our extender audience of physician assistants, nurse practitioners, and other providers can benefit from SBS, and particularly from your Cadaver Workshop?
Listen as internationally known dermatologist, David Goldberg, M.D., J.D., gives us insight into how to prevent skin cancer - as well as shares some of the latest and greatest advancements in dermatology in part 2 of his podcast series. Dr. Goldberg is known for his work using cutaneous lasers and other noninvasive facial and body rejuvenation techniques. He is active in clinical practice as the director of Skin Laser & Surgery Specialists of New York and New Jersey, and as a clinical professor of dermatology at Mount Sinai School of Medicine and Rutger’s New Jersey Medical School.
Don't forget to rate, subscribe or follow DermDocs, and leave us a five star review!
Topics he covers include:
-
As former Co-Vice President of the Skin Cancer Foundation, you know that even though improvements in detection, therapeutics, and surgery for skin cancer are increasing long-term survival, prevention is still the key. How will your session in the Cutaneous Oncology Symposium at the August's South Beach Symposium spotlight skin cancer prevention?
-
What are some strategies you use to encourage sunscreen use in your patients?
-
You earned your Medical Degree from Yale, and completed your dermatology residency and dermatologic surgery fellowship at New York University Medical Center. Do you have advice for medical students or residents interested in pursuing a career in dermatology, knowing it is one of the most competitive subspecialties?
-
Do you think attending a LiVDerm event could give students a competitive edge? Mentorship is essential - could networking at a LiVDerm event connect future dermatologists with industry mentors?
-
With expertise in both cosmetic and medical dermatology, what do you think are the biggest advancements in each field this year? How can providers incorporate these new technologies or strategies into their practice and how will they benefit their patients?
Listen as internationally known dermatologist, David Goldberg, M.D., J.D., gives us some of the latest tips and tricks about skin rejuvenation in this part I podcast special. Dr. Goldberg is known for his work using cutaneous lasers and other noninvasive facial and body rejuvenation techniques. He is active in clinical practice as the director of Skin Laser & Surgery Specialists of New York and New Jersey, and as a clinical professor of dermatology at Mount Sinai School of Medicine and Rutger’s New Jersey Medical School.
Don't forget to rate, subscribe or follow DermDocs, and leave us a five star review!
Topics he covers include:
-
You have published extensively on laser dermatology and will present a session at the upcoming South Beach Symposium on energy-based devices for body contouring. How do energy-based devices differ from lasers, and can you give some examples of a patient that would benefit from each type of treatment?
-
As a member of the South Beach Symposium Planning Committee, what informs the topics you put on the agenda each year? Do you rely most heavily on recent research developments, therapeutics showing promise in trials, or your personal experience with what see in your practice?
-
One session South Beach Symposium attendees look forward to each year is the Live Patient Injection Demonstration, which you'll be taking part in. What are some principles of using injectables for body contouring and rejuvenation that our audience can expect to learn?
Listen as Patrick Bitter Jr., MD, FAAD shares insights about why light is so important when it comes to keeping your skin healthy. You don't want to miss these tips from Dr. Bitter - who was just featured in the cover story of Top Doctor Magazine 's March 2022 issue for his discovery of pulsed light and its usefulness, effectiveness, and versatility in treating a multitude of skin problems, as well as delaying skin aging, and maintaining healthy skin, as an adjunct to a cosmetic surgical practice in the treatment of post surgical scars - in other words, finding the "fountain of youth".
Don't forget to rate, subscribe or follow DermDocs, and give us a five star review!
Topics he covers include:
- You'll present a session at the 2022 South Beach Symposium discussing energy-based devices for facial rejuvenation. Can you give listeners a glimpse of what will be covered?
- What technology would suggest for a patient with acne scarring or uneven skin texture who hasn't seen results from first-line treatments?
- You developed the FotoFacial Procedure; who is a candidate for this service and what are the benefits?
- The COVID-19 pandemic has revealed some unexpected challenges for providers in many medical subspecialties. Have you observed any new patient complaints, surge requests for certain procedures, or other phenomenons you attribute to the pandemic?
- Your practice is in California - SBS is launching a new event at the Terranea Resort in Southern California this Fall! Can you explain if patients on the West Coast have different aesthetic ideals than East Coast patients?
- What nuances do you think attendees at SBS WEST will experience in an agenda tailored to a West Coast audience?
Dr. Z. Paul Lorenc, M.D., shares insights about why science is your guide and anatomy is your savior. He will be leading the hands-on cadaver workshop at the South Beach Symposium this August, and you don't want to miss it! Other topics he covers include:
- Why is a mastery of facial anatomy principles non-negotiable for cosmetic dermatologists who offer soft tissue fillers?
- Can you explain the basic differences between facial fillers and neurotoxins - and how to use both injectables in the same patient successfully?
- You'll lead the intensive Hands-On Cadaver Workshop at the 2022 South Beach Symposium. Please Explain what attendees will experience during this comprehensive training - and how the skills gained will be actionable in their practices.
- You've pioneered some industry-defining cosmetic techniques and procedures. Can you explain how these minimally invasive services contribute to patient satisfaction, and if the availability of noninvasive cosmetic technologies has resulted in fewer requests for more invasive surgical procedures?
- "Science is your guide. Anatomy is your savior." Can you explain how this quote on your website exemplifies the cosmetic dermatology specialty, and how you'll infuse this concept into your instruction of the Hands-On Cadaver Workshop this year at SBS?
Dr. Doris Day, M.D., F.A.A.D., M.A. shares insights about the latest trends and new developments in dermatology today.
Dr. Glynis Ablon, M.D., F.A.A.D. shares some insightful knowledge about the latest developments in dermatology and how to keep your patients feeling confident and vivacious, including:
As a member of the South Beach Symposium Planning Committee, you help design and curate the agenda. How do you decide which topics should be covered; do you rely on issues or concerns you see in your practice, or emerging therapeutics/devices/technologies?
In your opinion, is it more beneficial for dermatologists to have either a cosmetic, medical, or surgical practice and build a reputation as an expert in one area, or is it more advantageous to offer many dermatologic services?
Dermatology is known as one of the most competitive medical specialties. What would your advice be to medical students or residents pursuing a dermatology fellowship and career?
The recent approval of JAK inhibitors to treat atopic dermatitis is an exciting development in medical dermatology. Are there any devices or technologies emerging on the aesthetic side you are excited about? Do you see any gaps in the current dermatologic training?
Do you see efforts by LiVDerm and South Beach Symposium to address those gaps (if any) and is that a draw for clinicians to seek conferences like ours?
Dr. Bruce Katz, MD, shares some emerging treatments in dermatology including:
- The global facial injectables market size is expected to reach USD 9.07 billion by 2028 (the market size stood at USD 4.46 billion in 2020): What does this mean for aesthetic medicine providers, are there more ways to capitalize on this growth other than simply offering injectables?
- Which new or emerging laser technology or treatment should providers have their eyes on, or consider offering in their practice if they don’t already?
- For someone interested in facial rejuvenation but hesitant to commit to surgery, which noninvasive or minimally invasive procedure delivers the best results with little downtime?
- You practice both clinical and aesthetic dermatology – which field has the most growth potential for new practitioners? If a dermatology student or resident were deciding between dermatologic subspecialties, what would your advice to them be?
- Your partnership with LiVDerm as faculty at many of our prestigious events draws quite a following. What do you think LiVDerm offers our attendees that other conferences do not? What are providers who’ve never been to a LiVDerm event missing?
- February is Black History Month – LiVDerm has dedicated resources and programming to address dermatologic conditions that disproportionately affect or burden people with skin of color (SOC) such as African Americans. What is your experience in this area, and how can the dermatology community lessen these disparities?
Brett King, MD, LivDerm faculty and a pioneer in utilizing JAK inhibitor therapy for treating atopic dermatitis discusses the best ways recently approved JAK inhibitors can be used in your clinical toolbox.
Dr. Peter Lio, MD, shares some highlights about the treatment of atopic dermatitis in pediatric patients including:
- Can you tell us about the number of emerging therapies for the treatment of atopic dermatitis in pediatric patients and how this has changed the treatment landscape?
- What is your personal approach to treating atopic dermatitis in pediatric patients?
- What made you decide to found the Chicago Integrative Eczema Center to prevent atopic dermatitis in children?
- Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric atopic dermatitis patients regarding treatment options?
- Are there any other tips that you recommend to your patients when explaining to them how to manage their skin diseases?
- If you could be known for one thing, what would it be?!
Candrice Heath, MD, discusses key takeaways regarding disparities in the treatment of atopic dermatitis and scalp/hair conditions in pediatric patients with skin of color, including:
- Can you highlight some of the systemic issues that contribute to a lack of knowledge about atopic dermatitis in patients of color, particularly in the pediatric patient population? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
- Can you discuss some of the more common hair and scalp conditions seen in pediatric patients of color, and why they are more commonly seen or more severe in patients of color?
- Are there any unique considerations that must be taken when discussing these conditions with the parents and caregivers in this patient population?
- Can you tell us which treatments for atopic dermatitis have been studied specifically in patients of color? Do you know if any of these treatments been studied specifically in pediatric patients of color?
- Is there anything else you’d like to add?
Susan Taylor, MD, shares some clinical pearls from regarding the treatment of acne patients with skin of color, including:
- Can you highlight some of the systemic issues that contribute to a lack of knowledge about acne in patients of color? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
- Can you explain why it is important to treat post-inflammatory hyperpigmentation alongside acne, particularly in patients of color?
- Are there any unique considerations that must be taken when prescribing treatment for acne patients with skin of color?
- Can you tell us which acne treatments have been studied specifically in patients of color, and briefly touch upon the safety and efficacy of those treatments?
- Is there anything else you’d like to add?
Andrew Alexis, MD, shares some highlights regarding the treatment of atopic dermatitis and psoriasis in patients with skin of color, including:
- Can you highlight some of the systemic issues that contribute to a lack of knowledge about acne in patients of color? (This is in reference to lack of diversity in clinical trials, lack of training involving skin of color, etc.)
- Can you explain why certain skin conditions, including atopic dermatitis and psoriasis, may be more difficult to diagnose in patients with skin of color?
- What is your personal approach to treating atopic dermatitis patients with skin of color?
- In what ways do you feel that dermatologists can continue to improve in caring for patients with skin of color?
- Is there anything else you’d like to add?
Amy McMichael, MD, Chair of the LiVDerm Deep Dive Racial Disparities in Dermatology program, shares highlights the current health disparities in dermatologic care for patients with skin of color, including:
- Can you give us a brief overview of the LiVDerm Deep Dive Racial Disparities program and why it is important to dermatologists?
- Can you highlight some of the systemic issues that specifically contribute to a lack of knowledge about dermatologic conditions in patients of color?
- Have you seen a change in the representation of patients with skin of color in clinical trials?
- Where do you feel dermatologists can continue to improve in terms of recognizing disparities and treating patients with skin of color?
- Is there anything else you'd like to add?
Mark Lebwohl, MD, discusses the new and emerging therapies for treatment of psoriasis, including:
Can you elaborate on the different classes of biologics currently indicated for treatment of psoriasis?
- What are some of the most promising therapies that will likely be part of the psoriasis treatment table in the near future?
- Do you foresee that they will be also approved for pediatric psoriasis patients, or only for the adult population?
- Where do you feel biologics fit in with the other approved treatments for psoriasis, or overall in the treatment regimen?
- Can you tell us what you feel is still needed in terms of developing new treatments for psoriasis?
Adelaide Hebert, MD, shares some highlights and clinical pearls about treatment of psoriasis in pediatric patients, including:
- What is your personal approach to treating psoriasis in pediatric patients compared to other age groups?
- Can you highlight the different class of therapeutics currently indicated to treat pediatric patients with psoriasis?
- Are there any considerations to be made when prescribing treatment for psoriasis in patients across the age spectrum, from infants to adolescents?
- How do you educate patients and families to deal with the psychological aspects of psoriasis, as well as with treatment adherence?
Latanya Benjamin, MD, shares clinical pearls about the management of atopic dermatitis in pediatric patients with skin of color, including:
- Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?
- What is your personal approach to treating AD in pediatric patients with skin of color?
- Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
Lawrence Schachner, MD, discusses recent developments in the pediatric atopic dermatitis treatment landscape, including:
- Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
- Dupilumab is currently approved for patients with atopic dermatitis aged 6 years and older. Do you foresee dupilumab being approved for even younger patients in the near future?
- How do emerging JAK inhibitors fit into the existing treatment landscape for pediatric patients with atopic dermatitis?
Candrice Heath, MD, shares some highlights from the Pediatric Skin of Color Symposium about the treatment of acne in pediatric patients with skin of color, including:
- What is your personal approach to treating acne in patients with skin of color?
- Can you tell us about the approved and emerging therapies for treatment of acne in pediatric patients? Have any of them been studied in patient populations with skin of color?
- Can you explain why it is important to treat both acne and post-inflammatory hyperpigmentation, particular in patients of color?
- How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?
Latanya Benjamin, MD, shares some highlights from the Pediatric Skin of Color Symposium at MOPD about the treatment of atopic dermatitis in pediatric patients with skin of color, including:
- Can you tell us about the number of emerging therapies for treatment of AD in pediatric patients and how this will change the treatment landscape?
- What is your personal approach to treating AD in pediatric patients with skin of color?
- Can you share some advice for dermatologists on communicating with parents and caretakers of pediatric AD patients regarding treatment options and at-home interventions?
Amy McMichael, MD, Chair of the CME Symposium "Diversity in Derm Treatments: Skin of Color" at SBS 2021, leads a panel discussion with Valerie Callender, MD, and Seemal Desai, MD, to share clinical pearls and key takeaways about treatment of dermatologic conditions in patients with skin of color.
Glenn Speer, PhD, has been working with dermatologists to manage his psoriatic arthritis symptoms for over 20 years. In this video interview, Glenn tells his story, including:
- Can you share with us your experience of your path to diagnosis?
- Can you tell us about what type of treatments you tried and how long and how long it took you to identify the best treatment?
- Can you share more with us about how PsA has affected both your personal and professional life?
- Do you have a message that you'd like to convey to those watching this interview, regarding how they can motivate their patients if a treatment doesn't work and encourage them to try the different recommended treatments, as well as adhere to those treatment?
Alice Gottlieb, MD, Chair of the CME symposium "Time to Think About Both Skin and Joint Disease: Optimizing the Diagnosis and Management of Psoriatic Arthritis" at SBS 2021, shares some clinical pearls about the dermatologist's role in screening and diagnosing psoriatic arthritis, including:
- Can you tell us about screening tools that are currently available for psoriatic arthritis patients?
- What is your personal approach to diagnosing psoriatic arthritis patients?
- What do you feel the dermatologist’s role is in treatment of psoriatic arthritis? Do you have any advice for dermatologists working with rheumatologists as a team approach?
Lawrence Schachner, MD, shares some clinical pearls about treatment of acne and antibiotic stewardship in pediatric patients, including:
- What do dermatologists need to keep in mind when prescribing treatments for pediatric patients with acne?
- How do these new acne treatments address the issue of antibiotic resistance?
- Can you tell us more about the effects of these new acne treatments on the microbiome?
Diane Berson, MD, shares additional clinical pearls on the treatment of acne and antibiotic stewardship, including:
- Can you discuss how the microbiome is affected in treatment of acne patients?
- Can you explain which antibiotics are better in terms of resistance?
- What are the core principles of antibiotic stewardship?
- What is your personal approach to minimizing antibiotic resistance in acne?
Jonette Keri, MD, shares some highlights about treatment of acne in preteen patients, including:
- What is your personal approach to treating acne in preteen patients compared to other age groups?
- What is your advice for dermatologists to keep in mind when treating preteen patients with acne?
- Can you tell us more about the efficacy and safety of these new acne medications for children and adolescents?
- How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?
James Del Rosso, DO, discusses new and emerging therapies for treatment of acne patients, including:
- What is your personal approach for exploring alternative treatments for acne patients beyond first-line therapies?
- Can you compare the emerging topical treatments for acne?
- What are some advantages with the newer topical retinoids?
- How do these new acne treatments address the issue of antibiotic resistance?
Candrice Heath, MD, shares clinical pearls about the treatment of acne in pediatric patients with skin of color, including:
What is your personal approach to treating acne in patients with skin of color?
Can you tell us about the approved and emerging therapies for treatment of acne in pediatric patients?
Have any of them been studied in patient populations with skin of color?
Can you explain why it is important to treat both acne and post-inflammatory hyperpigmentation, particular in patients of color?
How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?
Fernanda Schmidt, MD shares some clinical pearls about the evolving paradigms in AD, including:
- What are the inside-out and outside-in mechanisms of AD?
- Is there a difference between these mechanisms across the age spectrum – from children to adults?
- Can we halt the atopic march by repairing the skin, or is it more than “skin deep”?
Leon Kircik, MD discusses the potential role of emerging AD treatments, including:
- Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
- What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
- Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
- In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?
Lawrence Schachner, MD discusses clinical pearls on the diagnosis and treatment of pediatric AD, including:
- How do we make sure that we correctly diagnose atopic dermatitis? What are some clinical pearls you can share for our audience?
- Since now dupilumab is approved for children with atopic dermatitis, what is its role and where would it fit into the “Schachner ladder”?
- How do crisaborole and dupilumab fit into the long-term care of AD? For how long should they be used?
Neal Bhatia, MD discusses the potential role of JAKis in AD, including:
- What changes would JAKis bring to the treatment of AD in the near future?
- What are some JAKis currently under clinical development for AD?
- Do you foresee that JAKis will play a role in both adult and pediatric AD?
- Where do you think they will fit in with the other recently-approved treatments for AD, or overall in the treatment regimen?
- What are the long-term implications for dermatology practice?
Jonette Keri, MD, PhD, shares some highlights about acne evaluation and treatment across the age spectrum, including:
• How do we differentiate and grade acne across the age spectrum, from newborns to preteens?
• When is it necessary to refer, particularly to endocrinology or other specialties, for childhood acne that may be associated with an underlying endocrine disorder?
• What should we be using more of and less of in treating acne across the age groups?
• How do you educate patients and families to deal with the psychological aspects of acne, as well as with treatment adherence?
Diane Berson, MD, shares additional clinical pearls on the treatment of adult female acne, including:
• What are some typical acne presentations seen in adult women?
• Can acne in women persist beyond menopause?
• Can some of the newer non-oral contraceptives exacerbate acne flares? What are the options in this case?
• Is there a concern with hyperkalemia in patients taking spironolactone for acne?
• What should dermatologists keep in mind while treating acne in adult women?
James Del Rosso, MD, shares clinical pearls about common controversies and recent developments in acne therapy, including:
- What is your approach to minimizing antibiotic resistance in acne?
- Are the newer antibiotics better in terms of resistance?
- Why are dermatologists hesitant in using oral isotretinoin?
- What are some of the advantages with the newer topical retinoids?
- Should we pay more attention to truncal acne?
Michael Gold, MD, discusses additional takeaways on laser and light therapy for acne, including:
- How do you explain the absence of light and laser therapies from the global alliance acne treatment algorithm? Do you think that there is enough evidence to recommend their addition to the treatment guidelines?
- How do lasers/light therapies for acne challenge the current treatment status quo? How do they fit in with existing treatments?
- For what patient profiles (in terms of severity or type of acne) are they more appropriate?
- What are some key devices for acne treatment?